The anti-resorptive properties of tetracyclines (TCs) and their non-antimicrobial, chemically modified analogues (CMTs) have enormous therapeutic potential in medicine and dentistry. Osseous destructive diseases associated with excessive mammalian collagenase (matrix metalloproteinase) activity and collagen breakdown include malignancy, arthritis, and periodontitis. However, apart from the significant antimatrix metalloproteinase effects of TCs, TCs/CMTs are also potent inhibitors of osteoclast function (i.e., anti-resorptive). Thus, TCs can affect several parameters of osteoclast function and consequently inhibit bone resorption by (1) altering intracellular calcium concentration and interacting with the putative calcium receptor; (2) decreasing ruffled border area; (3) diminishing acid production; (4) diminishing the secretion of lysosomal cysteine proteinases (cathepsins); (5) inducing cell retraction by affecting podosomes; (6) inhibiting osteoclast gelatinase activity; (7) selectively inhibiting osteoclast ontogeny or development; and (8) inducing apoptosis or programmed cell death of osteoclasts. TCs/CMTs, as anti-resorptive drugs, may act similarly to bisphosphonates and primarily affect osteoclast function.
Athanasou NA, Hall P., d'Ardenne AJ, Quinn J., McGee JO (1988). A monoclonal antibody (anti-L-35) which reacts with human osteoclasts and cells of the mononuclear phagocyte system. Br J Exp Pathol69:309-319.
2.
Aubin JE, Heersche JNM, Kanehisa J, Okuda A, Turksen K, Opas M (1992). Osteoclast adhesion: the microfilaments and podosomes. In: The biological mechanisms of tooth movement and craniofacial adaptation. Davidovitch Z, editor. Birmingham, AL: EBSCO Media, pp. 97-104. Baron R (1989). Molecular mechanisms of bone resorption by the osteoclast. Anat Rec 224:317-324.
3.
Baron R, Neff L, Brown W, Courtoy PJ, Louvard D, Farquhar MG (1988). Polarized secretion of lysosomal
4.
enzymes: co-distribution of cation-independent mannose-6-phosphate receptors and lysosomal enzymes along the osteoclast exocytic pathway. J Cell Biol 106 :1863-1872. Bax CM, Shankar VS, Towhidul Alam AS, Bax BE, Moonga BS, Huang CL, et al. (1993). Tetracyclines modulate cytosolic Ca+2 responses in the osteoclast associated with "Ca+2 receptor" activation. Biosci Rep 13:169-174. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. (1993). Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197-250.
5.
Chambers TJ, Fuller K. (1985). Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoblastic contact. J Cell Sci76:155-165.
6.
Chambers TJ, McSheehy PM, Thomson BM, Fuller K. (1985). The effect of calcium regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinol116:234-239.
7.
Collin-Osdoby P., Oursler MJ, Webber D., Osdoby P. (1991). Osteoclast-specific monoclonal antibodies coupled to magnetic beads provide a rapid and efficient method of purifying avian osteoclasts. J Bone Miner Res6 :1353-1365.
8.
Delaisse JM, Vaes G. ( 1992). Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: Biology and physiology of the osteoclast. Rifkin BR, GayCV, editors. Boca Raton, FL: CRC Press, pp. 289-314.
9.
Donahue HJ, Iijima K., Goligorsky MS, Rubin CT, Rifkin BR (1992). Regulation of cytoplasmic calcium concentration in tetracycline treated osteoclasts. J Bone Miner Res7:1313-1318.
10.
Everts V., Delaisse JM, Korper W., Niehof A., Vaes G., Beertsen W. (1992). Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol150:221-231.
11.
Fleisch H (1983). Bisphosphonates: mechanism of action and clinical applications. In: Bone and mineral research. Peck WA, editor. Amsterdam: Excerpta Medica, pp. 319-357. Fleisch H (1991). Bisphosphonate pharmacology and use in the treatment of tumor induced hypercalcemic and metastatic bone disease. Drugs 42:919-944.
12.
Freije JM, Diez-Itza I., Balbin M., Sanchez LM, Blasco R., Tolivia J., et al. (1994). Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem269 :16766-16773.
13.
Gay CV, Ito MB, Schraer H (1984). Carbonic anhydrase activity in isolated osteoclasts. Metab Dis Rel Res 5:33-37. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. (1983). Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodont Res 18:516-526.
14.
Golub LM, Ramamurthy N, McNamara TF Gomes B, Wolff M, Casino A, et al. (1984). Tetracyclines inhibit tissue
15.
collagenase activity: a new mechanism in the treatment of periodontal disease. J Periodont Res 19:651-655.
16.
Golub LM, Wolff M., Lee HM, McNamara TF, Ramamurthy NS, Zambon J., et al. (1985). Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources . J Periodont Res20:12-23.
Golub LMRamamurthy NS, McNamara TF Greenwald RA, Rifkin BR (1991). Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med2:297-321.
19.
Golub LMSuomalainen K., Sorsa T. (1992). Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent2:80-90.
20.
Golub LM, Evans RT, McNamara TF, Lee HM, Ramamurthy NS (1994). A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. In: Inhibition of matrix metalloproteinases: therapeutic potential. Greenwald RA, Golub LM, editors. New York: Annals of the New York Academy of Sciences (proceedings). Vol. 732, pp. 96-111.
21.
Gomes BC, Golub LM, Ramamurthy NS (1984). Tetracyclines inhibit parathyroid hormone-induced bone resorption in organ culture. Experientia 40:12731275. Horton M, Rimmer E, Lewis D, Pringle JA, Fuller K, Chambers TJ (1984). Cell surface characterization of the human osteoclast: phenotypic relationship to other bone marrow cell types. J Pathol 144:281-291.
22.
Hughes DE, Wright KR, Uy HL, Sasaki A., Yoneda T., Roodman GD, et al. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res10:1478-1487.
23.
Hughes DEDai A., Tiffee JC, Li HH, Mundy GR, Boyce BF (1996). Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med2:1132-1136.
24.
Kameda T. Miyazawa K, Mori Y, Yuasa T, Shiokawa M, Nakamura Y, et al. (1996). Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun 220:515-519. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, et al. (1997). Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186:489-495.
25.
Knauper V. Will H, Lopez-Otin C Smith B, Atkinson SJ, Stanton H, et al. (1996). Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 271:17124-17131. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A. et al. (1997). Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthrit Rheum 40:1391-1399.
26.
Miller SC. Jee WSS (1975). Ethane-1-hydroxy-1,1-
27.
diphosphonate (EHDP): effects on growth and modeling of the rat tibia. Calcif Tissue Res 10:215-223. Montgomery EH (1989). Antibacterial antibiotics. In: Pharmacology and therapeutics for dentistry. Neidle EA, Yagiela JA, editors. St. Louis: The C.V. Mosby Company, pp. 511-555.
28.
Okahashi N., Nakamura I., Jimi E., Koide M., Suda T., Nishihara T. (1997). Specific inhibitors of vacuolar H(+)ATPase trigger apoptotic cell death of osteoclasts. J Bone Miner Res12:1116-1123.
29.
Oursler M., Collin-Osdoby P., Anderson F., Li L., Webber D., Osdoby P. (1991). Isolation of avian osteoclasts: improved techniques to preferentially purify viable cells. J Bone Miner Res6:375-385.
30.
Ozaki K., Takeda H., Iwahashi H., Kitano S., Hanazawa S. (1997). NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett410:297-300.
31.
Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996). A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res11:150-159.
32.
Prockop DJ, Kivirikko KI (1995). Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem64:403-434.
33.
Ramamurthy NS, Vernillo AT, Greenwald RA, Lee HM, Sorsa T., Golub LM, et al. (1993). Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res8:1247-1253.
34.
Rifkin B., Gomes B., Ramamurthy NS (1987). Effects of chemically-modified tetracycline on bone resorption in organ culture: preliminary observations (abstract). J Cell Biol105:216.
35.
Rifkin B., Vernillo A., Kleckner AP, Auszmann JM, Rosenberg LR, Zimmerman M. (1991). Cathepsin B and L activities in isolated osteoclasts . Biochem Biophys Res Commun179:63-69.
36.
Rifkin BR, Golub LM, Sanavi F., Vernillo AT, Kleckner AP, McNamara TF, et al. (1992a). Effects of tetracyclines on rat osteoblast collagenase activity and bone resorption in vitro. In: The biological mechanisms of tooth movement and craniofacial adaptation. Davidovitch Z, editor. Birmingham, AL : EBSCO Media, pp. 85-90.
37.
Rifkin BR, Ramamurthy NS, Gay CV (1992b). Effects of tetracyclines on acid production by isolated osteoclasts (abstract). J Dent Res71 (Spec Iss):1038.
38.
Rifkin BR, Vernillo AT, Golub LM (1993). Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol64:819-827.
39.
Rifkin BR, Vernillo AT, Golub LM, Ramamurthy NS (1994). Modulation of bone resorption by tetracyclines . In: Inhibition of matrix metalloproteinases: therapeutic potential. Greenwald RA, Golub LM, editors. New York: Annals of the New York Academy of Sciences (proceedings). Vol. 732. pp. 165-180.
40.
Rifkin BR, Golub LM, Ramamurthy NS, Vernillo AT (1996).
41.
Inhibition of bone resorption by tetracyclines. In: Biological mechanisms of tooth movement and craniotacial adaptation. Davidovitch Z, editor. Boston: Harvard Society for the Advancement of Orthodontics, pp. 357-363.
42.
Rowe DJ, Hausmann E. (1976). The alteration of osteoclast morphology by diphosphonate in bone organ culture. Calcif Tissue Res18:53-59.
43.
Sakamoto S., Sakamoto M. (1982). Biochemical and immunohistochemical studies on collagenase in resorbing bone in tissue culture. A novel hypothesis for the mechanism of bone resorption. J Periodont Res17:523-526.
44.
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65. Sato T, del Carmen Ovejero M, Hou P, Heegaard AM, Kumegawa M, Foged NT, et al. (1997). Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts. J Cell Sci 110:589-596.
45.
Schlesinger PH, Blair HC (1992). Bisphosphonates. In: Biology and physiology of the osteoclast. Rifkin BR, Gay CV, editors. Boca Raton, FL: CRC Press, pp. 397-418. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK (1996). Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50:1127-1138.
46.
Shankar VS, Bax CM, Bax BE, Alam AS, Moonga BS, Simon B., et al. (1993). Activation of the Ca+2 "receptor" on the osteoclast by Ni+2 elicits cytosolic Ca+2 signals: evidence for receptor activation and inactivation, intracellular Ca+2 redistribution, and divalent cation modulation . J Cell Physiol155:120-129.
47.
Sorsa T, Ding Y, Salo T, Lauhio A, Teronen 0, Ingman T, et al. (1994). Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and Western-blot assessment with special reference to their cellular sources in periodontal diseases. In: Inhibition of matrix metalloproteinases: therapeutic potential. Greenwald RA, Golub LM, editors. New York: Annals of the New York Academy of Sciences, Vol. 732, pp. 112-131. Stahle-Backdahl M, Sandstedt B, Bruce K, Lindahl A, Jimenez MG, Vega JA, et al. (1997). Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab Invest 76:717-728.
48.
Storm T, Steiniche T, Thamsborg G, Melsen F (1993). Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199-208. Teronen 0, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, et al. (1997). Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res 76:1529-1537.
49.
Teti A., Zambonin-Zallone A. (1992). Osteoclast cytoskeleton and attachment proteins . In: Biology and physiology of the osteoclast. Rifkin BR, Gay CV , editors. Boca Raton, FL: CRC Press, pp. 245-258.
50.
Uy HL, De La Mata J., Guise TA, Dallas M., Boyce B., Mundy GR, et al. (1994). Risedronate affects mature osteoclasts (ocl) but not ocl precursors in vivo (abstract). J Bone Miner Res9:S242.
51.
Vernillo A., Rifkin B. (1998). Collagenase and other osteoblast enzymes. In: Advances in organ biology. Zaidi M, editor. Greenwich, CT: JAI Press, Vol. 5B, pp.467-482.
52.
Vernillo AT, Ramamurthy NS, Lee HM, Mallya S., Auszmann J., Golub LM, et al. (1993). ROS and UMR osteoblast gelatinases: tetracycline inhibition (abstract). J Dent Res72:367.
53.
Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR (1994). The nonantimicrobial properties of tetracycline for the treatment of periodontal disease. Curr Opin Periodontol2:111-118.
54.
Vernillo AT, Ramamurthy NS, Golub LM, Greenwald RA, Rifkin BR (1997). Tetracyclines as inhibitors of bone loss in vivo . In: Studies in stomatology and craniofacial biology. Cohen MM Jr, Baum BJ, editors. Amsterdam: IOS Press , pp. 499-522.
55.
Zaidi M., Alam AS, Shankar VS, Bax BE, Bax CM, Moonga BS, et al. (1993). Cellular biology of bone resorption. Biol Rev Cambridge Philosoph Soc68:197-264.
56.
Zaidi M., Shankar VS, Tunwell R., Adebanjo OA, Mackrill J., Pazianas M., et al. (1995). A ryanodine receptor-like molecule expressed in the osteoclast plasma membrane functions in extracellular Ca+2 sensing . J Clin Invest96:1582-1590.
57.
Zambonin-Zallone A., Teti A., Carano A., Marchisio PC (1988). The distribution of podosomes in osteoclasts cultured on bone laminae: effect of Retinol. J Bone Miner Res3:517-523.
